Search research articles
Contact Us
Filters
Showing results (121-130 of 210) with videos related to
Page
of 21
Sort By:
The Lancet. Oncology
|
October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
JTO Clinical and Research Reports
|
November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Cancer Discovery
|
June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway
Pietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
JAMA Oncology
|
November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
Page
of 21
Search research articles
Search
Showing results (121-130 of 210) with videos related to
Sort By:
Page
of 21
The Lancet. Oncology
|
October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2020
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M Rudin, Mark M Awad, Alejandro Navarro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
JTO Clinical and Research Reports
|
November 13, 2023
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, et al.
Cancer Discovery
|
June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway
Pietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Journal for Immunotherapy of Cancer
|
November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
Joao V Alessi, Adam Price, Allison L Richards, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2024
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
Stefano Scalera, Biagio Ricciuti, Daniele Marinelli, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon, Jessica J Lin, Thomas Filleron, et al.
JAMA Oncology
|
November 17, 2022
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC
Mehrdad Rakaee, Elio Adib, Biagio Ricciuti, et al.
Page
of 21